[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516973":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":35,"centralContacts":42,"locations":52,"responsibleParty":72,"collaborators":75,"id":82,"slug":26,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":83,"sex":89,"minAge":90,"maxAge":26,"enrollmentInfo":91,"targetDuration":26,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":26,"overallStatus":54,"whyStopped":26,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"OHSU Knight Cancer Institute","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm I (iLIVE)","EXPERIMENTAL","Patients receive online access to an interactive weight loss website and participate in online group based resistance training sessions (iLIVE) on study. Patients also use a Fitbit fitness tracker and Aria smart scale while on study.",[13,14],"Other: Internet-Based Exercise Intervention","Other: Internet-Based Diet Intervention",{"label":16,"type":17,"description":18,"interventionNames":19},"Arm II (usual care)","ACTIVE_COMPARATOR","Patients receive usual care with access to online survivorship and exercise recommendations and use a Fitbit fitness tracker and Aria (registered trademark) smart scale while on study.",[20],"Other: Education Intervention",[22,27,31],{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"Internet-Based Exercise Intervention","Participate in online supervised, group resistance training sessions (iLIVE)",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Internet-Based Diet Intervention","Receive online access to an interactive website with a series of weekly self-directed and interactive sessions on various topics associated with diet and weight loss (iLIVE)",[9],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"Education Intervention","Receive usual care receiving educational information about diet and exercise for cancer survivors",[16],[36,39],{"name":37,"affiliation":5,"role":38},"Kerri Winters-Stone, PhD","PRINCIPAL_INVESTIGATOR",{"name":40,"affiliation":41,"role":38},"Wendy Demark-Wahnefried, PhD, RD","University of Alabama at Birmingham",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":26,"email":47},"Carolyn Guidarelli, MPH","CONTACT","503-346-0307","borsch@ohsu.edu",{"name":49,"role":45,"phone":50,"phoneExt":26,"email":51},"Sharon McCoy, MS","503-494-1676","mccoys@ohsu.edu",[53],{"facility":5,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"RECRUITING","Portland","Oregon","97239","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-122.67621,45.52345,{"lat":64,"lon":63},[67,71],{"name":68,"role":45,"phone":69,"phoneExt":26,"email":70},"Kerri Winters-Stone","503-494-0813","wintersk@ohsu.edu",{"name":68,"role":38,"phone":26,"phoneExt":26,"email":26},{"type":38,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Kerri Winters","Principal Investigator",[76,79,81],{"name":77,"class":78},"National Cancer Institute (NCI)","NIH",{"name":80,"class":6},"Oregon Health and Science University",{"name":41,"class":6},"100516973",false,"NCT06011499","Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE","Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors (iLIVE)","iLIVE","Inclusion Criteria:\n\n* INTERVENTION PARTICIPANTS: Age 18 or older\n* INTERVENTION PARTICIPANTS: Diagnosed with histologically confirmed prostate cancer\n* INTERVENTION PARTICIPANTS: Received \\>= 6 months of ADT any time in the past 10 years\n* INTERVENTION PARTICIPANTS: Completed radiotherapy, chemotherapy and\u002For surgery \\> 6 weeks prior to\n* INTERVENTION PARTICIPANTS: No intent to start adjuvant chemotherapy or radiotherapy within 6 months of enrollment\n* INTERVENTION PARTICIPANTS: Overweight or obese (body mass index \\> 25 kg\u002Fm2 to BMI ≤ 50).\n* INTERVENTION PARTICIPANTS: Evidence of frailty by meeting three or more of the following frailty criteria: weakness, slowness, fatigue, inactivity, and\u002For illness\n* INTERVENTION PARTICIPANTS: Not currently engaging in structured diet or resistance strength training exercise program\n* INTERVENTION PARTICIPANTS: Willing to be randomized into either study arm and adhere to study protocol\n* INTERVENTION PARTICIPANTS: Home internet sufficient for videoconferencing\n* INTERVENTION PARTICIPANTS: Signed informed consent\n* IMPLEMENTATION PARTICIPANTS: Be a key stakeholder (i.e., healthcare provider or administrative, or intervention participant \\[completers, partial completers, or no participation\\])\n* IMPLEMENTATION PARTICIPANTS: Verbal informed consent following receipt of an information sheet\n\nExclusion Criteria:\n\n* INTERVENTION PARTICIPANTS: Unintentional weight loss \\> 5% within the last year\n* INTERVENTION PARTICIPANTS: Contraindication to moderate intensity exercise\n* INTERVENTION PARTICIPANTS: Health or medical condition that affects weight status\u002Fbody composition (e.g., Cushing's syndrome, uncontrolled hyper-\u002Fhypo- thyroidism)\n* INTERVENTION PARTICIPANTS: Active malignancy (other than non-melanoma skin cancer)\n* INTERVENTION PARTICIPANTS: Not fluent in English and therefore incapable of answer survey questions, following directions during exercise or performance testing, and providing informed consent in English\n* INTERVENTION PARTICIPANTS: Currently taking or have taken creatine supplement in the month preceding baseline creatine testing","ALL","18 Years",{"count":92,"type":93},250,"ESTIMATED","INTERVENTIONAL",[96],"NA","This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity and frailty in men with prostate cancer who receive ADT.",[99],"Prostate Carcinoma","2026-05-06",{"date":102,"type":103},"2026-05-08","ACTUAL",{"date":105,"type":103},"2024-03-12",{"date":107,"type":93},"2027-12-31",{"name":5,"class":6},1]